Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Effects on Vascular Structure in Early Type 2 Diabetes
NCT05303857Phase 4Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Central (aortic) pulse pressure at 16 weeks. Started Mar 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05303857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303857.